Blar i ODA Open Digital Archive på forfatter "Holte, Harald"
-
Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-Radionuclide conjugate 177Lu-Lilotomab satetraxetan
Blakkisrud, Johan; Holtedahl, Jon Erik; Løndalen, Ayca; Dahle, Jostein; Bach-Gansmo, Tore; Holte, Harald; Nygaard, Stine; Kolstad, Arne; Stokke, Caroline (Journal of Nuclear Medicine;April 1, 2018; Vol. 59, no. 4, Journal article; Peer reviewed, 2018-08-28)177Lu-lilotomab satetraxetan is a novel antibody radionuclide conjugate (ARC) currently in a phase 1/2a first-in-human dosage escalation trial for patients with relapsed CD37+ indolent non Hodgkin lymphoma (NHL). The ... -
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Stokke, Caroline; Blakkisrud, Johan; Løndalen, Ayca; Dahle, Jostein; Martinsen, Anne Catrine Trægde; Holte, Harald; Kolstad, Arne (European Journal of Nuclear Medicine and Molecular Imaging;July 2018, Volume 45, Issue 7, Journal article; Peer reviewed, 2018-02-22)Purpose: 177Lu-lilotomab satetraxetan is a novel anti-CD37 antibody radionuclide conjugate for the treatment of non-Hodgkin lymphoma (NHL). Four arms with different combinations of pre-dosing and pre-treatment have been ...